enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Oxybutynin - Wikipedia

    en.wikipedia.org/wiki/Oxybutynin

    Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder.It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.

  3. Merck Gains FDA Approval for First OTC Patch for Overactive ...

    www.aol.com/news/2013-01-25-merck-gains-fda...

    The FDA has approved Merck's Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women, a condition that Merck says affects more than 20 million American women.

  4. 14 Overactive Bladder Treatments Doctors Recommend - AOL

    www.aol.com/lifestyle/14-overactive-bladder...

    The front-line treatment for overactive bladder are medications, either daily pills or taken as a preventative before specific occasions Dr. Linehan says. There are two main types: beta agonists ...

  5. Darifenacin - Wikipedia

    en.wikipedia.org/wiki/Darifenacin

    Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. [1] [2] [3] It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis.

  6. Fesoterodine - Wikipedia

    en.wikipedia.org/wiki/Fesoterodine

    Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.

  7. Mirabegron - Wikipedia

    en.wikipedia.org/wiki/Mirabegron

    Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. [8] [9] [3] In 2022, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

  8. Drug for overactive bladder could be made available over ...

    www.aol.com/drug-overactive-bladder-could-made...

    For premium support please call: 800-290-4726 more ways to reach us

  9. Vibegron - Wikipedia

    en.wikipedia.org/wiki/Vibegron

    Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. [1] [5] [6] Vibegron is a selective beta-3 adrenergic receptor agonist. [1] The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection. [5]